Table 2.
Clinical aspect of therapies targeting the IL-17 pathway.
| Disease | Sera | Biopsies | Cell type | SNPs or mutations | Therapy targeting Th17 pathway | Reference |
|---|---|---|---|---|---|---|
| Multiple sclerosis | IL-17A mRNA is detected in cerebrospinal fluid mononuclear cells | Myelin-reactive Th17+ cells are enriched and express high IL-22 and IFNγ | Anti-p40 subunit of IL-12/23 (ustekinumab) (no effect) | [73–75] | ||
| Rheumatoid arthritis | IL-17 ↑ | IL-17 ↑ | Synoviocytes express IL-1b and IL-6 in response to IL-17 | Anti-IL-6R (Tocilizumab); IL-1 receptor antagonist (anakinra); anti-IL17 (LY2439821, others) | [69, 72, 76–78] | |
| Systemic lupus erythematosus | IL-17 ↑ | IL-17 ↑ | [18, 70, 71] | |||
| Psoriasis | IL-17A, IL-22, and IL-23 ↑ | CD8+ T cells secreting IL-17 and IL-22 (Tc17 and Tc22, respectively) | IL-23 pathway | Anti-p40 subunit of IL-12 and IL-23 (ustekinumab) | [79–82] | |
| Inflammatory Bowel disease | IL-23 pathway | [83] | ||||
| Crohn's disease | IL-17+ (RORγT+ IL-23R+ and CCR6+cells) ↑ | Th17 (CD161+CD4+ T cells) | Anti-IL-6R (Tocilizumab); anti-p40 subunit of IL-12/23 (ustekinumab) | [76, 84–86] |